Cue Biopharma Inc To Host Business Update And Ongoing CUE-101 Clinical Trials Call Transcript
Greetings, and welcome to the Cue Biopharma update call. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn the conference over to Dan Passeri, Cue Biopharma's Chief Executive Officer. Thank you. You may begin.
Okay. Thank you, and good afternoon, everyone. We appreciate your time and interest in our update call regarding recent data and observations from our ongoing clinical trials of CUE-101, which is our first drug candidate representative of the IL-2-based CUE-100 series.
Joining me on today's call is Dr. Anish Suri, our President and Chief Scientific Officer; Dr. Ken Pienta, our acting Chief Medical Officer; and Dr. Matteo Levisetti, our Senior Vice President of Clinical Development.
So this conference is being recorded and will be available on our website for the next 30 days. As a reminder, and as shown here on Slide #2, this presentation and overview may contain some forward-looking statements. And any forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
